Avantor, Inc. Q3 FY2026 earnings call

Revival Program Progress:

• The 'Revival' initiative is delivering tangible results, evidenced by the return to organic revenue growth and operational improvements.
• Leadership team is now complete with the onboarding of CFO Todd Garner and CIO Mikey Santiago.
• Commercial execution in VWR has improved significantly, with approximately half of Q3 growth attributed to specific commercial initiatives rather than just market tailwinds.
• BMP is seeing increased manufacturing throughput and improved supply chain efficiency, including digital workflow implementations at key sites.

Operational and Digital Enhancements:

• Deployment of AI tools such as the Internal Sales Assistant (ISA) in VWR to enhance productivity and customer experience.
• Expansion of AI capabilities for cross-referencing product substitutes to identify sustainability and cost-saving opportunities.
• BMP manufacturing lines have exceeded design capacity targets, achieving near 99% overall equipment effectiveness.
• Continued investment in e-commerce platforms and supply chain optimization strategies.

End Market Dynamics:

• Recovery in demand is broadening, with strength in large pharma, biotech, and early-stage biotech customers in North America.
• Europe remains a lagging region due to challenging macroeconomic conditions, high energy costs, and government funding pressures.
• Asia shows good activity levels, though it represents a smaller portion of total revenue.

Financial Discipline:

• Robust free cash flow generation allows for balance sheet strengthening and continued investment.
• Adjusted net leverage ratio decreased to 3.1x, with a target to reduce it below 3x by year-end.

VWR Distribution and Services: Generated $1.23 billion in revenue, representing a 5.8% organic growth rate. Adjusted operating income was $119 million, with an adjusted operating margin of 9.7%. The segment's growth was primarily driven by higher volumes resulting from improved commercial execution and stronger end markets, although margins declined sequentially due to mix shifts, inflationary pressures, and growth investments.

Bioscience and MedTech Products (BMP): Generated $465 million in revenue, reflecting a 3.6% organic growth rate that exceeded expectations despite a 150 basis point headwind from unusual customer ordering patterns. Adjusted operating income was $123 million, achieving an adjusted operating margin of 26.6%, which remained flat year-over-year but increased sequentially due to higher volumes and favorable mix dynamics.

• Full Year 2026 Organic Revenue Growth: Raised to a range of 0.75% to 1.25%, implying Q4 organic growth of 2.5% to 4.5%.
• Full Year 2026 Adjusted EPS: Raised to $0.81–$0.83, up from previous estimates.
• Full Year 2026 Free Cash Flow: Increased to $520–$550 million.
• VWR Q4 Outlook: Expected to grow mid-single digits, assuming continuation of Q3 momentum.
• BMP Q4 Outlook: Expected to be flat to slightly positive organically, impacted by a 400 basis point headwind from discrete order timing comparisons.
• Adjusted EBITDA Margin: Guidance remains unchanged; management expects modest sequential expansion from Q3 to Q4.
• Foreign Exchange Impact: Expected to contribute approximately 75 basis points to full-year reported revenue growth, with a 150 basis point headwind anticipated in Q4.

• Macroeconomic Headwinds in Europe: High energy costs and government funding pressures continue to challenge demand in this important geography.
• Inflationary Pressures: Ongoing inflation, exacerbated by geopolitical conflicts, impacts costs across the business.
• Customer Ordering Patterns: Unusual or discrete ordering and shipment patterns, particularly in the serum business within BMP, create volatility and headwinds to growth.
• Pricing Lag: There is a lag between cost increases and price adjustments, meaning pricing recovery may not fully offset inflation immediately.
• Execution Risk: While progress is being made, the Revival program is ongoing, and failure to sustain operational improvements could hinder long-term growth.

Q: Casey Woodring asked about the sustainability of VWR’s growth, specifically how much was driven by large contract renewals versus other commercial initiatives like small/mid-sized accounts and e-commerce.

A: Emmanuel Ligner confirmed that while large contract renewals contributed, roughly half of the growth came from broader commercial actions, including strong performance in small/mid-sized accounts and e-commerce. He expressed confidence that these results are sustainable, supporting the expectation for mid-single-digit VWR growth in Q4.

Q: Daniel (on behalf of Vijay Kumar) asked why Q4 guidance implies a moderation in organic growth compared to Q3’s 5.2%, given similar corporate comps, and sought clarity on Avantor’s view of AI’s impact on growth.

A: Todd Garner explained that the moderation is largely due to a 400 basis point headwind in BMP caused by timing issues in electronic materials orders, while VWR is expected to maintain consistent mid-single-digit growth. Emmanuel Ligner added that AI is viewed as a significant industry tailwind that boosts pharma productivity, thereby increasing demand for research and development services provided by both VWR and BMP.

Q: Luke Sergott questioned whether margin pressure in VWR was due to discounting for contract renewals or if operational investments were yet to flow through, and asked about early wins in BMP facilities.

A: Steven Eck clarified that margin compression was primarily driven by unfavorable mix (VWR growing faster than higher-margin BMP) and inflation, rather than excessive discounting. Emmanuel Ligner highlighted that BMP is seeing underlying strength with positive book-to-bill ratios for three consecutive quarters and high-single-digit order growth in processed chemicals, indicating that supply chain and S&OP improvements are already yielding results.

Q: Yves Birstein requested details on the European market’s weakness relative to academia/government spending and wanted quantitative data on e-commerce improvements following the new CIO appointment.

A: Emmanuel Ligner noted that Europe lags due to budget constraints in academia and industrial suffering, particularly in Germany, but emphasized that their guidance assumes a static scenario, so any recovery would be a tailwind. Regarding e-commerce, he stated that the relaunch of vwr.com in early 2026 received positive feedback and that the new CIO is building a robust digital plan involving AI integration, with more details to be shared at the upcoming Investor Day.

Q: Daniel Arias asked for specific numbers on the net effect of pricing for 2026 and when further clarity on 2027 pricing might be available.

A: Steven Eck noted that pricing execution has improved significantly compared to the prior year, helping to recover costs better. Todd Garner specified that year-to-date pricing has been between 1% and 2%, which is still less than inflation rates, indicating they are chasing cost increases. He confirmed that quantification for 2027 will be discussed in detail during the Q4 earnings call in February.